Autres langues Eledon Pharmaceuticals, Inc.

Actions

ELDN

US28617K1016

Temps réel estimé Cboe BZX Autres places de cotation 17:10:55 25/04/2024			Varia. 5j.	Varia. 1 janv.
1,95 ^USD	-1,02 %		+0,50 %	+11,11 %

28/03	Eledon Pharmaceuticals, Inc. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
25/03	Eledon Pharmaceuticals annonce le recrutement d'un douzième participant à l'essai Tegoprubart ; les actions montent après les heures de bureau	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results	28/03
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours	25/03
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection	25/03
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection	25/03
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21/03
Sector Update: Health Care	21/03
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human	21/03
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human	21/03
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human	21/03
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	14/02
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	14/02
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook	04/01
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/12
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/12
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference	29/11
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results	09/11
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference	08/11
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	02/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Eledon Pharmaceuticals, Inc.

Actions

ELDN

US28617K1016

Autres langues

Filtres